Mold-active azole antifungals are commonly prescribed for the prevention of invasive fungal infections in lung transplant recipients. Each agent exhibits a unique pharmacologic profile, an understanding of which is crucial for therapy selection and optimization. This article reviews pharmacologic considerations for three frequently-used azole antifungals in lung transplant recipients: voriconazole, posaconazole, and isavuconazole. Focus is drawn to analysis of drug-interactions, adverse drug reactions, pharmacokinetic considerations, and the role of therapeutic drug monitoring with special emphasis on data from the post-lung transplant population.
CITATION STYLE
Klatt, M. E., & Eschenauer, G. A. (2021). Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. Journal of Fungi, 7(2), 1–16. https://doi.org/10.3390/jof7020076
Mendeley helps you to discover research relevant for your work.